Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees worldwide and 850 employees in the UK.

Since it was founded in 1885, Boehringer Ingelheim has remained a family owned company whose distinctly independent structure means that it is not constrained by the short-term needs of individual shareholders and can focus on the future with long-term strategies of vision and leadership.  The family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. 

The company is known for many prescription medicines and also consumer health care products, in addition Boehringer Ingelheim is also on the forefront of researching, developing and manufacturing biopharmaceuticals.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

Boehringer Ingelheim is involved in three key healthcare areas: Prescription Medicines, Over-The-Counter (OTC) products and Animal Health.  In Human Pharmaceuticals, the company operates four major R&D sites and three smaller specialized sites worldwide, which focus on six major therapeutic areas:

  • Respiratory diseases
  • Cardio-metabolic diseases
  • Oncology
  • Neurological diseases
  • Immunology
  • Infectious diseases

Boehringer Ingelheim is dedicated to the research and development of medical products to improve, sustain and care for life. Their product portfolio is supported by a wide range of services, designed to help the medical profession deliver the best possible healthcare to patients. 

The company has built a reputation for providing effective and genuine products for the treatment of UK’s leading diseases:

  • Chronic obstructive pulmonary disease (COPD): which affects nearly a million people in the UK?
  • Heart attack (Myocardial Infarction): causes around 180,000 hospital admissions in the UK each year.
  • Secondary stroke prevention: Each year about 110,000 people in the UK have a first stroke, and about 30,000 have a recurrent stroke. Strokes cause over 53,000 deaths every year in the UK.
  • Thromboembolic disease: annually kills more people in the UK than the total combined number of deaths from breast cancer, prostate cancer, AIDS and traffic accidents.
  • High blood pressure: 1 in 4 middle aged adults in the UK has high blood pressure.
  • HIV/AIDS: an estimated 83,000 are living with this disease in the UK.
  • Parkinson’s: affects 1 person per 500 in the UK (a total of around 120,000).

In the above areas Boehringer Ingelheim has met medical needs and improved the lives of patients. For the future the company is developing pioneering medicines to treat patients suffering from:

  • Stroke due to atrial fibrillation (abnormal heart rhythm): atrial fibrillation affects more than half a million people in the UK and is a leading cause of stroke.
  • Diabetes: over 2.6 million people suffer from diabetes in the UK and up to half a million people with diabetes have the condition and don’t know it.
  • Oncology: 1 in 3 people in the UK develop cancer during their lives.

In January 2011 Boehringer Ingelheim signed a global agreement with Eli Lilly to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. The alliance will leverage the collective scientific expertise and business capabilities of two leading research-driven pharmaceutical companies to address patient needs arising from the growing global diabetes epidemic.  On a global scale Boehringer Ingelheim invest 21% of net sales from their Prescription Medicine business into Research & Development, which has ensured a very healthy product pipeline.

Boehringer Ingelheim also has a strong presence in the over-the-counter (OTC) sector. Key OTC products include

  • Vitamins & Supplements
  • Constipation Treatment
  • Stool Softeners
  • Antispasmodics
  • Male Urinary

Flomax Relief®MR is the latest OTC medicine which is a once daily capsule treatment for the urinary symptoms of an enlarged prostate (Benign Prostatic Hyperplasia), in men aged 45-75.  A condition that affects 1 in 4 men over the age of 40 in the UK.

Boehringer Ingelheim is dedicated to the research and development of medical products to improve, sustain and care for life.  Boehringer Ingelheim states the following;

“Value through Innovation is our corporate vision, our headline goal, and has helped us build on our strength and make the most of our distinctive character.

Our mission, in the UK, is to improve the health and well being of people and animals through being part of an independent, innovative, research and development driven company”.

Boehringer Ingelheim Limited
Ellesfield Avenue
UK  RG12 8YS

Tel: +44 (0) 1344 424600